Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cancer Medicine|March 25, 2018
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancerJeffrey L Vacirca, Arlene Chan, Klára Mezei, et al.
JAMA Oncology|June 2, 2022
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical TrialMiguel Martin, Roberto Hegg, Sung-Bae Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2026
Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trialKomal Jhaveri, Hope S Rugo, Javier Cortés, et al.
The New England Journal of Medicine|May 31, 2023
Capivasertib in Hormone Receptor-Positive Advanced Breast CancerNicholas C Turner, Mafalda Oliveira, Sacha J Howell, et al.
The Lancet. Oncology|August 30, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trialMafalda Oliveira, Hope S Rugo, Sacha J Howell, et al.
Gynecologic Oncology|October 23, 2024
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER studyKan Yonemori, Valentina Boni, Kim Gun Min, et al.
Pageof 2